Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 23, 2022 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Announces Appointment of William Heiden to Board of Directors

ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...
May 17, 2022 16:01 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conference

ROCKVILLE, MD, May 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...
May 03, 2022 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results

Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumorsTargeting mid-2022 start of Phase 1...
April 25, 2022 16:12 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call

ROCKVILLE, MD, April 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
March 03, 2022 16:01 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, March 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
February 28, 2022 07:00 ET | Source: MacroGenics, Inc.

MacroGenics Announces Executive Promotion

ROCKVILLE, MD, Feb. 28, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
February 24, 2022 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and 2021 Financial Results

Initiating Phase 1 dose escalation study of MGC018 in combination with lorigerlimab (formerly MGD019) in coming weeksPrioritizing MGD024 as lead CD3-based DART® molecule targeting CD123 and...
February 14, 2022 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call

ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
February 03, 2022 16:01 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Feb. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
November 03, 2021 16:01 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Nov. 03, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...